bezisterim
-
[Abstract] S331: Results of a Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Bezisterim (NE3107) in LC (ADDRESS-LC),2026,Markham
Abstract Background: Long COVID continues to burden a significant percentage of the population with debilitating symp-toms, including cognitive impairment ("brain fog"), fatigue, post-exertional malaise (PEM), and sleep disturbance, contributing to a poor quality of life (QoL). Evidence...- Chandelier
- Thread
- address-lc bezisterim biovie conference abstract long covid
- Replies: 4
- Forum: Long Covid research
-
Closed A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID (ADDRESS-LC)
Post copied from News from the USA The Department of Defense has "announced the approval of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD) to evaluate Bezisterim (NE3107) for treating neurological symptoms associated with long COVID." The funding is...- RaviHVJ
- Thread
- address-lc bezisterim biovie clinical trial long covid neurological
- Replies: 94
- Forum: Recruitment into current ME/CFS research studies